Literature DB >> 9811528

Interleukins 4 and 13 upregulate expression of cd44 in human colonic epithelial cell lines.

L K Trejdosiewicz1, R Morton, Y Yang, R E Banks, P J Selby, J Southgate.   

Abstract

Interleukin 4 (IL-4) inhibits carcinoma cell growth and promotes expression of differentiation-associated products by normal and malignant epithelial cells. The effects of IL-4 and IL-13 on expression of the CD44 transmembrane adhesion receptor were examined in human epithelial cell lines of colonic (HT-29, CaCo-2, DLD-1, T84), breast (MCF-7, ZR75-1) and liver (Hep-G2, PLC/PRF/5) origins as well as mitogen-activated and resting peripheral blood lymphocytes (PBL) and T cell lines (Jurkat, HUT78). Liver and Jurkat cells were negative for CD44. Colonic, breast and HUT78 cells expressed CD44 constitutively and all except DLD-1 and HUT78 also expressed CD44 splice variant (CD44v) epitopes. All cell lines expressed IL-4 receptors, but IL-4 and IL-13 induced upregulation of CD44 only in the colonic cell lines. CD44v was also upregulated, but there was no de novo induction of CD44v in variant-negative cells and no de novo expression of CD44 in the CD44(-) lines. CD44 upregulation in mitogen-activated PBL was not increased by IL-4 and IL-13 and was not inhibited by neutralizing antibodies. Other cytokines tested [interferon gamma (IFN-gamma, tumour necrosis factor alpha (TNF-alpha), transforming growth factor beta1 (TGF-beta1) and IL-6] did not affect CD44 core epitope expression in the cell lines tested. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9811528     DOI: 10.1006/cyto.1998.0361

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  11 in total

1.  The heparan sulfate proteoglycan form of epithelial CD44v3 serves as a CD11b/CD18 counter-receptor during polymorphonuclear leukocyte transepithelial migration.

Authors:  Ke Zen; Dan-Qing Liu; Li-Min Li; Celia X-J Chen; Ya-Lan Guo; Bihn Ha; Xi Chen; Chen-Yu Zhang; Yuan Liu
Journal:  J Biol Chem       Date:  2008-12-10       Impact factor: 5.157

2.  Expression of CD44 on bile ducts in primary sclerosing cholangitis and primary biliary cirrhosis.

Authors:  S M Cruickshank; J Southgate; J I Wyatt; P J Selby; L K Trejdosiewicz
Journal:  J Clin Pathol       Date:  1999-10       Impact factor: 3.411

3.  Elevated IL-13Ralpha2 in intestinal epithelial cells from ulcerative colitis or colorectal cancer initiates MAPK pathway.

Authors:  Debasmita Mandal; Alan D Levine
Journal:  Inflamm Bowel Dis       Date:  2010-05       Impact factor: 5.325

4.  The lL-8 and IL-13 gene polymorphisms in inflammatory bowel disease and colorectal cancer.

Authors:  Anna Walczak; Karolina Przybylowska; Lukasz Dziki; Andrzej Sygut; Cezary Chojnacki; Jan Chojnacki; Adam Dziki; Ireneusz Majsterek
Journal:  DNA Cell Biol       Date:  2012-06-28       Impact factor: 3.311

5.  High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6.

Authors:  B Xu; U Broome; B-G Ericzon; S Sumitran-Holgersson
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

6.  Expression of gastrin precursors by CD133-positive colorectal cancer cells is crucial for tumour growth.

Authors:  Audrey Ferrand; Mauro S Sandrin; Arthur Shulkes; Graham S Baldwin
Journal:  Biochim Biophys Acta       Date:  2009-01-15

Review 7.  Altered glycosylation in inflammatory bowel disease: a possible role in cancer development.

Authors:  B J Campbell; L G Yu; J M Rhodes
Journal:  Glycoconj J       Date:  2001 Nov-Dec       Impact factor: 2.916

8.  Interleukin-4 induces a CD44high /CD49bhigh PC3 subpopulation with tumor-initiating characteristics.

Authors:  Holger H H Erb; Fabian Guggenberger; Frédéric R Santer; Zoran Culig
Journal:  J Cell Biochem       Date:  2018-01-19       Impact factor: 4.429

Review 9.  Possible Roles of Interleukin-4 and -13 and Their Receptors in Gastric and Colon Cancer.

Authors:  Xujun Song; Benno Traub; Jingwei Shi; Marko Kornmann
Journal:  Int J Mol Sci       Date:  2021-01-13       Impact factor: 5.923

10.  IL-13 is a driver of COVID-19 severity.

Authors:  Alexandra N Donlan; Tara E Sutherland; Chelsea Marie; Saskia Preissner; Benjamin T Bradley; Rebecca M Carpenter; Jeffrey M Sturek; Jennie Z Ma; G Brett Moreau; Jeffrey R Donowitz; Gregory A Buck; Myrna G Serrano; Stacey L Burgess; Mayuresh M Abhyankar; Cameron Mura; Philip E Bourne; Robert Preissner; Mary K Young; Genevieve R Lyons; Johanna J Loomba; Sarah J Ratcliffe; Melinda D Poulter; Amy J Mathers; Anthony J Day; Barbara J Mann; Judith E Allen; William A Petri
Journal:  JCI Insight       Date:  2021-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.